CG Invites Co., Ltd.
Financials
Valuation Metrics
CG Invites Co., Ltd.'s Market Cap is ₩661B. At end of 2025 it was ₩1143B. Ranked #1542 of 2,436 in KR market (top 63%), #895 of 1,649 on KOSDAQ (top 54%), #172 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 66.13B KRW | KR#1,542/2,436 Sec#172/234 |
| Revenue | 28.60B KRW | KR#2,046/2,436 Sec#142/234 |
| Net Income | -12.96B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 216.86B KRW | KR#1,232/2,436 Sec#90/234 |
| Net Assets | 112.84B KRW | KR#1,311/2,436 Sec#106/234 |
| Employees | 80 | KR#1,793/2,436 Sec#149/234 |
| Value | ||
| P/B | 0.59x | KR#961/2,436 Sec#47/234 |
| P/S | 2.31x | KR#1,898/2,436 Sec#111/234 |
| FCF Yield | -30.37% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -11.49% | KR#1,926/2,436 Sec#149/234 |
| ROA | -5.98% | KR#1,938/2,436 Sec#147/234 |
| Op. Margin | -86.30% | KR#2,298/2,436 Sec#171/234 |
| Revenue Growth | 39.21% | KR#371/2,436 Sec#35/234 |
| Financial Health | ||
| Debt Ratio | 192.18% | KR#1,648/2,436 Sec#186/234 |
| Total Debt | 43.79B KRW | KR#1,037/2,436 Sec#72/234 |
| FCF | -20.08B KRW | KR#1,901/2,436 Sec#180/234 |
| Cash | 8.98B KRW | KR#1,732/2,436 Sec#141/234 |
| Current Ratio | 0.46x | KR#2,272/2,436 Sec#220/234 |
| Performance | ||
| 1Y Return | -47.59% | KR#2,021/2,436 Sec#187/234 |
| 1M Return | -14.00% | KR#1,980/2,436 Sec#195/234 |
| From 52W High | -56.68% | KR#1,547/2,436 Sec#133/234 |
| 1Y MDD | -62.82% | KR#1,575/2,436 Sec#125/234 |
| Trading | ||
| Volume | 175,489 shares | KR#636/2,436 Sec#61/234 |
| Foreign Own. | 2.58% | KR#1,030/2,436 Sec#101/234 |
| Per Share | ||
| EPS | -35 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,096 KRW | KR#2,269/2,436 Sec#203/234 |
Company Info
CG Invites, established in 2000, changed its name in 2023 and was listed on KOSDAQ in 2006. The bio company specializes in digital genome new drug development, Printed Circuit Board/hot pack manufacturing, and healthcare solutions. It commercialized the anti-inflammatory analgesic 'Acellex' as South Korea's first new drug and is conducting US FDA clinical trials for molecular targeted anti-cancer drugs. CG Invites is establishing a healthcare platform that merges genome analysis with artificial intelligence and big data, aiming to become a leading company in the genome industry. The company is headquartered in Gangseo-gu, Seoul.